Cellectis S.A. · EURONEXT:ALCLS
Cellectis — Investor Presentation (June 2018)
29 slides from Cellectis's investor presentation, June 2018
Slide 1: Gene Edited CAR-T
GENE EDITED CAR-T Focusing on Effective Therapies Cellectis, June 2018
Slide 2: Forward-looking Statements
Forward-looking Statements T H I S P R E S E N TAT I O N C O N TA I N S “ F O RWA R D - L O O K I N G ” S TAT E M E N T S T H AT A R E B A S E D O N O U R M A N A G E M E N T ’ S C U R R E N T E X P E C TAT I O N S A N D A S S U M P T I O N S A N D O N I N F O R M AT I O N C U R R E N T LY AVA I L A
Slide 3: 1. Allogeneic CAR-T
d5 ; 1. ALLOGENEIC CAR-T
Slide 4: The "Allogeneic" CAR-T Concept
The “Allogeneic” CAR-T Concept n Lessons of 2017: I. CAR-Ts are here to stay II. 2 CAR-T BLAs approved by FDA III. Allogeneic concept validated IV. Sales benchmark for autologous CARTs n Allogeneic CAR-Ts: major uncertainties lifted ✓ ◻ Industrialized manufacturing process ✓ ◻ TALEN® gene editing in
Slide 5: How it works
How it works Allogeneic CAR T-Cells Through Gene Editing CS1 or Chimeric Antigen Receptor Tumor Recognition Allogeneic CAR T Cell Gene Editing TALEN® Nuclease 5
Slide 6: The Benefits Of UCARTs
The Benefits Of UCARTs UCARTs = Cellectis’ Allogeneic CAR T-Cells Market access ! Ability to release large amounts of product in advance ! Easily available at hospitals ! Can address patient populations that are deficient in T-cells Cost of treatment ! Possibility to lower the price range of CART th
Slide 7: A Strategic Alliance in Gene-Edited CAR-T
A Strategic Alliance in Gene-Edited CAR-T Leading the way in the allogeneic CAR-T arena A team made of big pharma partners and leading biotechs strongly financed Kite’s Former Leadership team >1 year to clinic Phase 1 dose escalation in multi-centric trials BCMA UCART19 Expansion EGFRVII UCART123 Ph
Slide 8: 2. Leading the Gene Edited CAR-T Space
2. Leading the Gene Edited CAR-T Space 8
Slide 9: Rich Allogeneic CAR-T Pipeline
Rich Allogeneic CAR-T Pipeline Addressing Unmet Medical Need With Proven Targets Program Indication Preclinical Manufacturing IND Filing1 Phase I Ph II Ph III UCART192 ALL (PALL) (Servier / Allogene) ALL (CALM) AML UCART123 BPDCN UCART22 B-ALL UCARTCS1 MULTIPLE MYELOMA Ø 3 programs in clinic: UCART1
Slide 10: UCART19: Initial Proof Of Concept In ALL Patients
UCART19¹ Initial Proof Of Concept In ALL Patients Tumor cell Ø 1st patient dosed in June 2015 (compassionate) Ø Phase I trials started in June 2016 in EU, in 2017 in the US Ø Multiple recruiting centers (EU and the US) Ø 17 patients treated disclosed UCART19 (9 adults and 8 pediatric)² ¹ UCART19 is
Slide 11: UCART19 Early Clinical Data
UCART19 Early Clinical Data Interim Ph1 Dose Escalation In Pediatric & Adult ALL Patients Ø Expansion of UCART19 and preliminary signs of efficacy in line with early autologous CAR-T Phase I results published in past years Ø Proof of Concept of efficacy of redosing in one patient Dose Level Lymphode
Slide 12: UCART123 in AML and BPDCN
UCART123 in AML and BPDCN Product Attributes And Pre-clinical Data UCART123 attributes § Anti-CD123 CAR expression to redirect T-cells to tumor antigens § Suicide gene for safety § TCR disruption to avoid GvHD Encouraging pre-clinical efficacy data § Significant improvement compared to Cytarabine st
Slide 13: UCART123 Dosing Schedule
UCART123 Dosing Schedule First wholly-controlled CAR-T in the clinic ! AML Phase 1 dose-escalation trial ongoing at Weill Cornell & MD Anderson Cancer Center ! First patient dosed in June 2017 Dose Escalation (mTPI) Phase (R/R AML) Expansion Phase DL3 5.05x106/kg RR AML DL2 6.25x105/kg N=18-37 DL1 2
Slide 14: UCART123 Protocol Amendment
UCART123 Protocol Amendment Main changes to the revised protocol § Increase of dose levels: ü DL1 increased from 6.25x104 to 2.5x105 UCART123 cells per kg. DL2 & DL3 now respectively at 6.25x105 and 5.05x106. DL-1 is now at 1.25x105. ü The product’s safety and tolerability profile allowed Cellectis
Slide 15: UCART22
UCART22 Product Attributes And Pre-clinical Data UCART 22 Rationale § Both CD22 and CD19 are expressed on various B-cells § CD22 expression frequently maintained in CD19-negative blasts1 Strong anti-tumour activity § UCART22 is highly efficient at eradicating tumors in vivo § UCART22 cells result in
Slide 16: UCART22 Objective for patient enrolment
UCART22 Objective for patient enrolment § Relapsed / refractory adult ALL patients first § Potential to expand § Enrolment open to CD19 treatment naïve patients § Open also to anti-CD19 pre-treated relapsing patients § Selection of strong CD22 expressing B-malignant cells (>2,000 CD22/cell) § First
Slide 17: UCARTCS1: Targeting Multiple Myeloma
UCARTCS1 Targeting Multiple Myeloma Unmet Medical Need Target Antigen ! > 30,000 patients / year in the US ! Well proven target with elotuzumab (BMS/ Abbvie) as PoC ! High relapse rate, median OS of 9 months ! CS1 (SLAMF7) is highly expressed on MM cancer cells ! CS1 is expressed on CD8 T-cells UCAR
Slide 18: UCARTCS1 Anti-tumor activity
UCARTCS1 Anti-tumor activity: high performance with re-dosing 100 75 Vehicle Percent survival UCARTCS1 3E6 50 UCARTCS1 3E6 redosing UCARTCS1 10E6 UCARTCS1 10E6 redosing 25 0 0 10 20 30 40 50 60 70 80 90 100 110 Times (days) Day 0 Day 25 Treatment 1 Treatment 2 18
Slide 19: 3. Gene-Editing Platform TALEN
3. Gene-Editing Platform TALEN ® 19
Slide 20: TALEN High Yield Gene Editing
TALEN® High Yield Gene Editing High Single Knock Out and Knock In Efficiencies TRAC Knock Out CAR Knock In at TRAC Locus 95.2% TCRab 79.8% TCRab CAR 95.2% Single Knock-Out ~80% Single Knock-In 20
Slide 21: Control of TALEN Off-Target Effect
Control of TALEN® Off-Target Effect Use of engineered RVDs to discriminate between ON and OFF-site Ø Educated utilization of engineered RVDs to discriminate HBB loci preventing OFF-site cleavage HBB ON-Site 25 ON-Site OFF-site 20 Mutation frequency (%) OFF-SITE 15 ON-site/OFF-site > 94 % identity HB
Slide 22: High Yield Multiplex Gene Editing
High Yield Multiplex Gene Editing Combining Knock-Out and/or Knock-In in T-cells Key Results TRAC TALEN® + CAR n 88% double targeted gene inactivation B2M TCR and B2M TRAC NK inhibitor @ B2M n 60% double targeted gene insertion CAR insertion at TCR NK inhibitor at B2M 22 CAR @ TRAC
Slide 23: Next Gen. CARTs To Target Solid Tumors
Next Gen. CARTs To Target Solid Tumors Synthetic Biology For High Performance UCARTs Example of targeted integration at CD25 locus ! IL12 contributes to anti tumor activity (Th1, NK, CD8) ! I.V. IL12 shows systemic adverse effects (BM, Liver, mucus membranes) ! Local On-Target IL12 secretion may avo
Slide 24: 4. Acceleration of Manufacturing Capacity
4. Acceleration of Manufacturing Capacity 24
Slide 25: Allogeneic CAR-T – GMP Manufacturing
Allogeneic CAR-T – GMP Manufacturing An integrated system combining gene editing and CAR-T manufacturing Ø Successful GMP manufacturing of UCART19, UCART123, UCART22 Ø GMP manufacturing of UCARTCS1 started Ø Full QC system in place, cleared for clinical trials in the EU and by the FDA 25
Slide 26: An Outstanding Experience in CAR-T
An Outstanding Experience in CAR-T Acceleration of timelines through previous proof-of-concept studies Ø UCART19 in ALL patients • Phase I dose escalation studies ongoing • Expected to enter multi-centric Phase II studies in 2019 Ø UCART123 in AML and BPDCN patients • Clinical hold lifted in Novembe
Slide 27: Expected Milestone Timeline
Expected Milestone Timeline Strong progress expected over the next 18 months 2018 2019 Q1 Q2 Q3 Q4 Q1 Q2 UCART19 Ph1 Dose Escalation Ongoing Interim data update Expansion UCART123 Ph1 Dose Escalation Ongoing Interim data update Expansion UCART22 Manufacturing IND Filing Interim data update UCART CS1
Slide 28: The Cellectis Group
The Cellectis Group ∼70,6% ownership § NASDAQ: CLLS § EURONEXT GROWTH: ALCLS § c.$500M IN CASH (WITH CALYXT) § NASDAQ: CLXT § c. $100M IN CASH § IMMUNO-ONCOLOGY / CAR T § BASED IN MINNESOTA § THERAPEUTIC GENE EDITING § CONSUMER FOCUS § GENE THERAPY § HIGH VALUE ASSET Gene editing is the link 28
Slide 29: Thank You
THANK YOU Cellectis S.A. 8, rue de la Croix Jarry 75013 Paris – France Cellectis, Inc. 430 East 29th Street 10016 New York, NY – USA investors@cellectis.com